FDA Approval Summary: Daratumumab for Treatment of Multiple Myeloma After One Prior Therapy

On November 21, 2016, the U.S. Food and Drug Administration granted regular approval to daratumumab in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy. Approval was base...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncologist
Autors principals: Bhatnagar, Vishal, Gormley, Nicole J., Luo, Lola, Shen, Yuan Li, Sridhara, Rajeshwari, Subramaniam, Sriram, Shen, Guoxiang, Ma, Lian, Shord, Stacy, Goldberg, Kirsten B., Farrell, Ann T., McKee, Amy E., Pazdur, Richard
Format: Artigo
Idioma:Inglês
Publicat: AlphaMed Press 2017
Matèries:
Regulatory Issues: FDA
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5679834/
https://ncbi.nlm.nih.gov/pubmed/28904172
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0229
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars